Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  13,292 results for ""Cytochrome P-450 CYP3A""

Your Filters

Language : english
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Early Prediction and Impact Assessment of CYP3A4-Related Drug-Drug Interactions for Small-Molecule Anticancer Drugs Using Human-CYP3A4-Transgenic Mouse Models.

  • Authors : Damoiseaux D; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (D.D., J.H.B., A.D.R.H., T.P.C.D.); Utrecht Institute of Pharmaceutical Sciences (J.H.B.) and Department of Clinical Pharmacy, University Medical Center Utrecht (A.D.R.H.), Utrecht University, Utrecht, The Netherlands

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacokinetics ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology ; Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/metabolism

  • Source: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Oct 16; Vol. 52 (11), pp. 1217-1223. Date of Electronic Publication: 2024 Oct 16.Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model:

Record details

Read More Add to Saved list
×
Academic Journal

Value of Assessing 1-Hydroxymidazolam in Drug-Drug Interaction Studies with Midazolam as a Substrate of Cytochrome P450 3A.

  • Authors : Magliocca M; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.; Berger B

Subjects: Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/metabolism ; Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/administration & dosage ; Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/pharmacokinetics

  • Source: Journal of clinical pharmacology [J Clin Pharmacol] 2024 Sep; Vol. 64 (9), pp. 1123-1129. Date of Electronic Publication: 2024 May 26.Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604

Record details

Read More Add to Saved list
×
Academic Journal

Novel Silybin-Conjugated Chitosan Polymeric Micelles for Improving the Oral Absorption of Doxorubicin Based on the Inhibition of P-gp and CYP3A4.

  • Authors : Yang Y; Department of Pharmacy, Guilin Medical University, No. 1 Zhiyuan Road, Guilin 541199, People's Republic of China.; Chen Y

Subjects: Chitosan*/Chitosan*/Chitosan*/chemistry ; Micelles* ; Doxorubicin*/Doxorubicin*/Doxorubicin*/pharmacology

  • Source: Biomacromolecules [Biomacromolecules] 2024 Nov 11; Vol. 25 (11), pp. 7146-7155. Date of Electronic Publication: 2024 Oct 17.Publisher: American Chemical Society Country of Publication: United States NLM ID: 100892849 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co-Administered with CYP3A4 Inhibitors.

  • Authors : Umehara K; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Parrott N

Subjects: Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/pharmacokinetics ; Drug Interactions* ; Models, Biological*

  • Source: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2024 Oct; Vol. 116 (4), pp. 1130-1140. Date of Electronic Publication: 2024 Jul 18.Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535

Record details

Read More Add to Saved list
×
Academic Journal

Drug-induced enzyme activity inhibition and CYP3A4 genetic polymorphism significantly shape the metabolic characteristics of furmonertinib.

  • Authors : Zhou Q; Institute of Molecular Toxicology and Pharmacology, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.; Ye Z

Subjects: Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/genetics ; Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/metabolism ; Rats, Sprague-Dawley*

  • Source: Toxicology [Toxicology] 2024 Sep; Vol. 507, pp. 153903. Date of Electronic Publication: 2024 Aug 03.Publisher: Elsevier Country of Publication: Ireland NLM ID: 0361055 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-3185

Record details

Read More Add to Saved list
×
Academic Journal

A drug-drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5-lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam.

  • Authors : Knöchel J; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Panduga V

Subjects: Midazolam*/Midazolam*/Midazolam*/pharmacokinetics ; Midazolam*/Midazolam*/Midazolam*/administration & dosage ; Drug Interactions*

  • Source: British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Sep; Vol. 90 (9), pp. 2180-2187. Date of Electronic Publication: 2024 Jun 03.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

The CYP3A inducer dexamethasone affects the pharmacokinetics of sunitinib by accelerating its metabolism in rats.

  • Authors : Lu GR; Department of Gastroenterology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.; Wang RZ

Subjects: Sunitinib*/Sunitinib*/Sunitinib*/pharmacokinetics ; Dexamethasone*/Dexamethasone*/Dexamethasone*/pharmacokinetics ; Dexamethasone*/Dexamethasone*/Dexamethasone*/pharmacology

  • Source: Chemico-biological interactions [Chem Biol Interact] 2024 Nov 01; Vol. 403, pp. 111228. Date of Electronic Publication: 2024 Sep 05.Publisher: Elsevier Country of Publication: Ireland NLM ID: 0227276 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7786

Record details

Read More Add to Saved list
×
Academic Journal

Predicting Food-Drug Interactions between Piperine and CYP3A4 Substrate Drugs Using PBPK Modeling.

  • Authors : Lin F; School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310058, China.; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Subjects: Polyunsaturated Alkamides*/Polyunsaturated Alkamides*/Polyunsaturated Alkamides*/metabolism ; Piperidines*/Piperidines*/Piperidines*/pharmacokinetics ; Piperidines*/Piperidines*/Piperidines*/pharmacology

  • Source: International journal of molecular sciences [Int J Mol Sci] 2024 Oct 11; Vol. 25 (20). Date of Electronic Publication: 2024 Oct 11.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

Record details

Read More Add to Saved list
×
Academic Journal

Identification of reversible OATP1B1 and time-dependent CYP3A4 inhibition as the major risk factors for drug-induced cholestasis (DIC).

  • Authors : Kastrinou-Lampou V; Pharmacokinetic Sciences, BioMedical Research, Novartis, Basel, Switzerland.; Preclinical Safety, BioMedical Research, Novartis, Basel, Switzerland.

Subjects: Cholestasis*/Cholestasis*/Cholestasis*/chemically induced ; Cholestasis*/Cholestasis*/Cholestasis*/metabolism ; Liver-Specific Organic Anion Transporter 1*/Liver-Specific Organic Anion Transporter 1*/Liver-Specific Organic Anion Transporter 1*/metabolism

  • Source: Archives of toxicology [Arch Toxicol] 2024 Oct; Vol. 98 (10), pp. 3409-3424. Date of Electronic Publication: 2024 Jul 18.Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0417615 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

1β-Hydroxydeoxycholic Acid as an Endogenous Biomarker in Human Plasma for Assessment of CYP3A Clinical Drug-Drug Interaction Potential.

  • Authors : Xue Y; Clinical Pharmacology, Pharmacometrics & Bioanalysis, Bristol-Myers Squibb, Princeton, New Jersey (Y.X., L.W., R.H., B.M., A.G., J.X.S.); Regeneron Pharmaceuticals Inc., Tarrytown, New York (M.C.)

Subjects: Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/metabolism ; Drug Interactions* ; Biomarkers*/Biomarkers*/Biomarkers*/blood

  • Source: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Aug 14; Vol. 52 (9), pp. 966-974. Date of Electronic Publication: 2024 Aug 14.Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model:

Record details

Read More Add to Saved list
×
  • 1-10 of  13,292 results for ""Cytochrome P-450 CYP3A""